ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novo Nordisk has agreed to acquire the biotechnology company Cardior Pharmaceuticals for about $1 billion. Cardior specializes in targeting noncoding RNA for heart therapies and has a compound called CDR132L in Phase 2 trials to treat heart failure. If approved, the oligonucleotide would be a first-in-class therapy for the disease. In January, Novo Nordisk reached a $500 billion market value, bolstered by its blockbuster drugs Ozempic and Wegovy, which alone accounted for more than 90% of the company’s sales in 2023.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter